MyoKardia Inc. (MYOK)

61.32
3.47 6.00
NASDAQ : Health Technology
Prev Close 57.85
Open 58.00
Day Low/High 57.35 / 61.83
52 Wk Low/High 39.01 / 67.78
Volume 1.09M
Avg Volume 276.20K
Exchange NASDAQ
Shares Outstanding 46.12M
Market Cap 2.57B
EPS -1.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

MyoKardia To Participate In September Investor Conferences

MyoKardia To Participate In September Investor Conferences

SOUTH SAN FRANCISCO, Calif., Aug.

MyoKardia Begins Dosing In Phase 1 Clinical Study Of MYK-224 For Hypertrophic Cardiomyopathy

MyoKardia Begins Dosing In Phase 1 Clinical Study Of MYK-224 For Hypertrophic Cardiomyopathy

Topline Results Expected in Mid-2020

MyoKardia Launches 2nd Annual MyoSeeds™ Research Grants Program To Advance Independent Research In Heart Disease

MyoKardia Launches 2nd Annual MyoSeeds™ Research Grants Program To Advance Independent Research In Heart Disease

Pre-Application Letters of Intent are Due September 13 for the 2019-2020 Funding Cycle

MyoKardia Reports Second Quarter 2019 Financial Results

MyoKardia Reports Second Quarter 2019 Financial Results

Announces Last Patient to be Enrolled in EXPLORER-HCM Phase 3 during the Week of  August 12 th; Topline Data Accelerated to 2 nd Quarter 2020 Topline Phase 2 Clinical Data from MAVERICK-HCM and MYK-491 on Track for Fourth Quarter 2019 Company to Host...

MyoKardia To Present At 2019 Wedbush PacGrow Healthcare Conference

MyoKardia To Present At 2019 Wedbush PacGrow Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Aug.

MyoKardia To Report Second Quarter 2019 Financial Results On Wednesday, August 7, 2019

MyoKardia To Report Second Quarter 2019 Financial Results On Wednesday, August 7, 2019

SOUTH SAN FRANCISCO, Calif., July 31, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc.

MyoKardia Announces HCM Program Updates: Accelerates Timing For Mavacamten Topline Phase 3 Data; Re-acquires U.S. Royalty Rights To HCM Programs From Sanofi

MyoKardia Announces HCM Program Updates: Accelerates Timing For Mavacamten Topline Phase 3 Data; Re-acquires U.S. Royalty Rights To HCM Programs From Sanofi

EXPLORER-HCM Patient Screening Closes Ahead of Schedule - Initial Results Now Anticipated in the Second Quarter of 2020 Royalty Purchase Creates Additional Economic Value for MyoKardia's Emerging HCM Treatment Portfolio SOUTH SAN FRANCISCO, Calif.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ACB, ECHO, EPAY, HMTV, MYOK, NVDA, PFIE, TGE, TU Downgrades: BIIB, HBB, KEQU, MGYR, OBCI, OLP, PTMN Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Moderna, MyoKardia Are Among Cutting-Edge Biotech Stocks for 2019

Moderna, MyoKardia Are Among Cutting-Edge Biotech Stocks for 2019

Moderna only went public in December, and is already creating a buzz.

Bears Are Doing an EKG Test on MyoKardia

Bears Are Doing an EKG Test on MyoKardia

A close below $44 will cause the bulls to throw in the towel and gains above $68 will do the same to the bears.

We Want Bad News, Bears: Cramer's 'Mad Money' Recap (Tuesday 10/30/18)

We Want Bad News, Bears: Cramer's 'Mad Money' Recap (Tuesday 10/30/18)

Jim Cramer says we actually want some bad news because definitive weaker news now drives stocks up and strong news takes them down.

MyoKardia Begins Patient Dosing In Phase 1b Clinical Study Of MYK-491 In Dilated Cardiomyopathy Patients

MyoKardia Begins Patient Dosing In Phase 1b Clinical Study Of MYK-491 In Dilated Cardiomyopathy Patients

Topline Results from First-in-Human Phase 1 Study of MYK-491 in Healthy Volunteers Demonstrated Tolerability and Increased Contractility

MyoKardia Presents Data From Study Of Machine Learning Algorithm Intended To Identify Obstructive Hypertrophic Cardiomyopathy Using A Wearable Biosensor

MyoKardia Presents Data From Study Of Machine Learning Algorithm Intended To Identify Obstructive Hypertrophic Cardiomyopathy Using A Wearable Biosensor

Digital Health Data from Substudy of PIONEER-HCM Presented in Late-Breaker at American Heart Association Scientific Sessions

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: FORK, FUSB, LUK, PCTY, ROCK, XRAY Downgrades: AIV, CATM, CCRN, DRAD, EDGW, FOGO, MYOK, RIG, RVLT, SBRA, WRE Initiations: LKSD Read on to get TheStreet Quant Ratings' detailed report:

TheStreet Quant Rating: C- (Hold)